Seguir
Kirsi Ketola
Kirsi Ketola
Afiliación desconocida
Dirección de correo verificada de utu.fi
Título
Citado por
Citado por
Año
The master neural transcription factor BRN2 is an androgen receptor–suppressed driver of neuroendocrine differentiation in prostate cancer
JL Bishop, D Thaper, S Vahid, A Davies, K Ketola, H Kuruma, R Jama, ...
Cancer discovery 7 (1), 54-71, 2017
3532017
Using online game-based platforms to improve student performance and engagement in histology teaching
S Felszeghy, S Pasonen-Seppänen, A Koskela, P Nieminen, K Härkönen, ...
BMC medical education 19, 1-11, 2019
2662019
High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth
K Iljin, K Ketola, P Vainio, P Halonen, P Kohonen, V Fey, RC Grafström, ...
Clinical Cancer Research 15 (19), 6070-6078, 2009
2422009
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative …
RE Kast, JA Boockvar, A Brüning, F Cappello, WW Chang, B Cvek, ...
Oncotarget 4 (4), 502, 2013
2042013
Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress
K Ketola, M Hilvo, T Hyötyläinen, A Vuoristo, AL Ruskeepää, M Orešič, ...
British journal of cancer 106 (1), 99-106, 2012
1962012
Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer
P Vainio, S Gupta, K Ketola, T Mirtti, JP Mpindi, P Kohonen, V Fey, ...
The American journal of pathology 178 (2), 525-536, 2011
1712011
High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion
L Lehtinen, K Ketola, R Mäkelä, JP Mpindi, M Viitala, O Kallioniemi, K Iljin
Oncotarget 4 (1), 48, 2013
1302013
PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A–mediated inactivation in human malignant glioma
P Puustinen, MR Junttila, S Vanhatupa, AA Sablina, ME Hector, ...
Cancer research 69 (7), 2870-2877, 2009
1132009
Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells
K Ketola, P Vainio, V Fey, O Kallioniemi, K Iljin
Molecular cancer therapeutics 9 (12), 3175-3185, 2010
1022010
High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer
P Vainio, JP Mpindi, P Kohonen, V Fey, T Mirtti, KA Alanen, M Perälä, ...
PloS one 7 (6), e39801, 2012
952012
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
S Taavitsainen, N Engedal, S Cao, F Handle, A Erickson, S Prekovic, ...
Nature communications 12 (1), 5307, 2021
702021
Regulation of tumor cell plasticity by the androgen receptor in prostate cancer
JL Bishop, A Davies, K Ketola, A Zoubeidi
Endocr Relat Cancer 22 (3), R165-R182, 2015
592015
Microglial amyloid beta clearance is driven by PIEZO1 channels
H Jäntti, V Sitnikova, Y Ishchenko, A Shakirzyanova, L Giudice, IF Ugidos, ...
Journal of Neuroinflammation 19 (1), 147, 2022
532022
Targeting Lyn regulates Snail family shuttling and inhibits metastasis
D Thaper, S Vahid, KM Nip, I Moskalev, X Shan, S Frees, ME Roberts, ...
Oncogene 36 (28), 3964-3975, 2017
382017
Targeting prostate cancer subtype 1 by forkhead box M1 pathway inhibition
K Ketola, RSN Munuganti, A Davies, KM Nip, JL Bishop, A Zoubeidi
Clinical Cancer Research 23 (22), 6923-6933, 2017
362017
CD44s assembles hyaluronan coat on filopodia and extracellular vesicles and induces tumorigenicity of MKN74 gastric carcinoma cells
K Härkönen, S Oikari, H Kyykallio, J Capra, S Hakkola, K Ketola, ...
Cells 8 (3), 276, 2019
302019
Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells
K Ketola, O Kallioniemi, K Iljin
PloS one 7 (12), e51470, 2012
302012
The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
PR Braadland, H Ramberg, HH Grytli, A Urbanucci, HK Nielsen, ...
Molecular Cancer Research 17 (11), 2154-2168, 2019
292019
Molecular and functional links between neurodevelopmental processes and treatment-induced neuroendocrine plasticity in prostate cancer progression
R Kaarijärvi, H Kaljunen, K Ketola
Cancers 13 (4), 692, 2021
202021
Axon guidance-related factor FLRT3 regulates VEGF-signaling and endothelial cell function
S Jauhiainen, JP Laakkonen, K Ketola, PI Toivanen, T Nieminen, ...
Frontiers in physiology 10, 224, 2019
202019
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20